PubMed Health⌕ Search

Biomedical subjects

S Ia Tazina

Publications and source records attributed to S Ia Tazina.

8 recordsLinked to original sources
PubMed2006

[Significance of C-reactive protein detection in patients with primary infective myocarditis].

The importance of the problem of primary infective endocarditis (PIE) has become much greater during the last years due to an increase in its incidence, serious early diagnostic difficulties, and high lethality, which makes study of its new diagnostic criteria necessary. The paper presents data on the role of C-reactive protein (CRP) in PIE diagnosis. The authors show that high CRP levels evidence prominent infective-and-toxic manifestations of the disease and that dynamic measurement of CRP levels in patients with infective myocarditis allows monitoring the effectiveness of the therapy and may be applied to the prognosis of the disease.

Adolescent↗
PubMed2001

[Diagnosis of myocardial lesions in infectious endocarditis].

To decide on treatment policy and specify prognosis in infectious endocarditis (IE) it is necessary to investigate myocardium. This is better to do using most informative criteria of myocardial affection--structural and geometrical changes of the left ventricle, various focal lesions, high-grade ventricular extrasystole, supraventricular tachycardia, atrioventricular block of various degree.

Adult↗
PubMedDate not supplied

[Clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia with concomitant cardiovascular diseases].

The aim of the study was assessment of clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia (BPH) and concomitant cardiovascular disease. A total of 62 BPH patients with cardiovascular disease (ischemic heart disease, hypertension) having indications for alpha-adrenoblockers (mean age 74 +/- 11 years, 58-85) received terazosine in a dose 1-5 mg for 2 months. Clinical efficacy of terazosine was assessed by IPSS scale, residual urine, maximal voiding velocity. Safety of the drug was controlled by monitoring of arterial pressure, ECG, echo-CG. All the tests were made before therapy, on the treatment week 2, 4 and 8. The response was 90.3%. Overall symptoms score decreased by 37.0%, quality of life score rose by 23.8%. Amount of residual urine fell by 64.8%, maximal voiding velocity increased by 36.6%. Moderate effects of the drug (vertigo, weakness) occurred in 11.3% patients for 1 or 2 days after start of the therapy and were due to a moderate fall of arterial pressure in normotensive patients. Later artertial pressure stabilized, ECG registered no exacerbations of ischemic heart disease, no anginal attacks, no change in cardiac rhythm. Thus, terazosine (setegis) is effective and safe in BPH patients with cardiovascular disease. Pretreatment consultation of the cardiologist is desirable for correction of basic antianginal therapy.

Administration, Oral↗